Wednesday, November 11, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 29, 2026

Qualcomm Is Down 37% From Its High and Reports Wednesday. Is the Stock a Buy?

View original at nasdaq.com
Qualcomm Is Down 37% From Its High and Reports Wednesday. Is the Stock a Buy? Key Points Qualcomm reports fiscal third-quarter results after the market closes on Wednesday, July 29…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The consensus analyst rating on Qualcomm is hold, with an average price target of $221.23, about 36% above the current price of $162.88.

    60% confidence
  • A custom silicon engagement with a leading hyperscaler remains on track for initial shipments later this calendar year.

    60% confidence
  • Qualcomm expects handset revenue from Chinese customers to bottom in the fiscal Q3 quarter and return to sequential growth in the following quarter.

    60% confidence
  • Qualcomm delivered results in line with guidance, reflecting solid execution navigating a challenging memory environment.

    60% confidence
  • The author would rather wait for more information before buying Qualcomm stock, even at the risk of missing a rebound.

    60% confidence

Data points we hold from this source

Qualcomm Incorporated · stock price162.88 USD
Qualcomm Incorporated · market share221.23 USD
Qualcomm Incorporated · cash3.7 USD
Qualcomm Incorporated · margin72 percent
Qualcomm Incorporated · eps2.65 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com
Qualcomm Is Down 37% From Its High and Reports Wednesday. Is the Stock a Buy? — Source | Via News | Via News